Nature Medicine, Published online: 31 March 2025; doi:10.1038/s41591-025-03607-9
A detailed case report shows that neoadjuvant combination immunotherapy can activate antitumor immunity and drive clinical benefit in newly diagnosed glioblastoma, revealing avenues for further research that could shift the treatment landscape to improve survival.
